Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01459380
Title Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

fallopian tube cancer

peritoneal carcinoma

ovarian cancer

Therapies

Carboplatin

Doxorubicin

Veliparib

Bevacizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora Colorado 80045 United States Details
Augusta University Medical Center Augusta Georgia 30912 United States Details
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637 United States Details
University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa 52242 United States Details
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287 United States Details
Memorial Sloan-Kettering Cancer Center New York New York 10065 United States Details
Case Western Reserve University Cleveland Ohio 44106 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
Hillcrest Hospital Cancer Center Mayfield Heights Ohio 44124 United States Details
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 United States Details
Women and Infants Hospital Providence Rhode Island 02905 United States Details
Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field